Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma |
| |
| Affiliation: | 1. Department of Internal Medicine, Divisions of HematologyOncology;2. Department of Internal Medicine, Divisions of Metabolism, Endocrinology, and Diabetes,;3. Department of Radiology, University of Michigan, Ann Arbor, Michigan.;1. Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway;2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;3. Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland;4. Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø;5. Women and Children''s Division, Norwegian National Advisory Unit on Women''s Health, Oslo University Hospital, Oslo;6. Department of Bowel Cancer Screening, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway;1. Departamento de Química/Instituto Universitario Mixto de Tecnología Química UPV-CSIC, Universitat Politècnica de València, Avenida de los Naranjos s/n, E-46022 Valencia, Spain;2. Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9 E-28040 Madrid, Spain;3. Departamento de Química Orgánica, Universidad de Valencia, Dr. Moliner 50, E 46100 Burjasot, Spain |
| |
| Abstract: | ObjectiveTo describe successful long-term tumor control in metastatic adrenocortical carcinoma, a relatively rare tumor with limited treatment options outside of surgery.MethodsWe present the clinical, radiologic, and pathologic findings in a patient with failure of or intolerance to conventional treatments for metastatic adrenocortical carcinoma.ResultsA 48-year-old man with adrenocortical carcinoma had disease progression with systemic therapies including mitotane, 5-fluorouracil, streptozotocin, bevacizumab, and external beam radiation therapy. Treatment with all chemotherapeutic drugs was ceased, and he was prescribed mebendazole, 100 mg twice daily, as a single agent. His metastases initially regressed and subsequently remained stable. While receiving mebendazole as a sole treatment for 19 months, his disease remained stable. He did not experience any clinically significant adverse effects, and his quality of life was satisfactory. His disease subsequently progressed after 24 months of mebendazole monotherapy.ConclusionMebendazole may achieve long-term disease control of metastatic adrenocortical carcinoma. It is well tolerated and the associated adverse effects are minor. (Endocr Pract. 2011;17:e59-e62) |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
